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(Communicated by E. Beutler, M.D., 6 September 2005)Abstract
We describe the molecular study in a cohort of 120 Portuguese patients with the clinical diagnosis of Gilbert syndrome and in one with the
diagnosis of Crigler–Najjar syndrome type II, as well as a prenatal diagnosis of Crigler–Najjar syndrome type I. Among the 120 unrelated
patients with Gilbert syndrome, 110 were homozygous for the [TA]7 allele ([TA]7/[TA]7), and one patient was a compound heterozygote for two
different insertions ([TA]7/[TA]8). The remaining 9 patients were heterozygous for the TA insertion ([TA]6/[TA]7). Additional studies in these 9
patients revealed heterozygosity for the c.674T>G, c.488_491dupACCT and c.923G>A mutations, in 1, 1 and 4 patients, respectively. The patient
with Crigler–Najjar syndrome type II was a compound heterozygote for [TA]7 and the c.923G>A mutation. The undocumented polymorphisms
c.-1126C>T and c.997-82T>C were also detected in the course of this study. Prenatal diagnosis in a family with a boy previously diagnosed as
Crigler–Najjar syndrome type I and homozygosity for the c.923G>A mutation revealed that the fetus was unaffected.
Homozygosity for the [TA] insertion was found to be the most frequent cause of GS in our population. Identification of further mutations in the
UGT1A1 gene was also seen to contribute significantly towards diagnosis.
D 2005 Elsevier Inc. All rights reserved.Keywords: Gilbert syndrome; Crigler–Najjar syndrome; UGT1A1; Hyperbilirubinemia; MutationsIntroduction
Water-insoluble bilirubin, which results from breakdown
products of heme [1–5], is a toxic compound. Hepatic
glucuronization of this insoluble bilirubin is catalyzed by
isoenzyme 1A1 of UDP-glucuronosyltransferase (UGT1A1),
which is essential for efficient biliary excretion of bilirubin [1–1079-9796/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.bcmd.2005.09.002
* Corresponding author.
E-mail address: elisio.costa@ipb.pt (E. Costa).5]. Genetic alterations causing absence, or severe reduction, of
UGT1A1 enzymatic activity result respectively in Crigler–
Najjar syndrome type I and type II [5–9]. The clinical
classification of Crigler–Najjar syndrome types I and II is
based on the bilirubin levels, the presence of kernictus and the
reduction of the bilirubin levels upon administration of
phenobarbital or other enzyme-inducing agents [4,5,10]. Mild
hyperbilirubinemia, usually less than 50 Amol/L, is associated
with Gilbert syndrome and thought to reflect a small reduction
in UGT1A1 activity (approximately 30%) [10–12]. Gilbertiseases 36 (2006) 91 – 97
www.els
Table 1
Primers used in the amplification of the UGT1A1 exons and promoter region
UGT1A1
region









Exon 2 UGT1A1-2F 5VTCTATCTCAAACACGCATGCC
UGT1A1-2R 5VGGCAGGGAAAAGCCAAATCTA
Exon 3 UGT1A1-3F 5VTTGCCAGTCCTCAGAAGCCTT
UGT1A1-3R 5VATGCCCTTGCAGAAATTTGC
Exon 4 UGT1A1-4F 5VTGCAAGGGCATGTGAGTAACA
UGT1A1-4R 5VAAGCCAAGATTGCACCACTG
Exon 5 UGT1A1-5F 5VGAGGATTGTTCATACCACAGG
UGT1A1-5R 5VGCACTCTGGGGCTGATTAAT
a From Ref. [18].
b Fluorochrome labeled primer (Ned).
E. Costa et al. / Blood Cells, Molecules, and Diseases 36 (2006) 91–9792syndrome is characterized by a chronic, nonhemolytic uncon-
jugated hyperbilirubinemia in the absence of liver disease or
overt hemolysis [4,5]. Serum bilirubin concentration fluctuates
during fasting, physical exercise, stress, intermittent illness or
menstruation [4,5,10]. On the basis of serum bilirubin levels,
3–10% of the general population is estimated to have Gilbert
syndrome [10,13,14].
The UGT1A1 enzyme is encoded by five exons located at
the 3V end of the UGT1A locus and is expressed only in the
liver. The first mutation in this gene was described in 1992. It
was a nonsense mutation found in homozygosity in a patient
with Crigler–Najjar syndrome [6]. Only in 1995 were
mutations in this gene found to be correlated with Gilbert
syndrome [7]. To date, more than 50 mutations causing Gilbert
syndrome and Crigler–Najjar syndrome have been identified,
most of which are missense or nonsense mutations, and almost
all were first described in association with Crigler–Najjar
syndrome. The main cause of Gilbert syndrome in all
populations studied to date is a TA insertion in the repetitive
TATA-box sequence of the gene promoter, which normally
consists of six TA repeats [9,15–17]. This [TA]7 allele is
extremely common, occurring with an estimated frequency of
38,7% in the white population and 16% in the Asian population
[9]. In persons with African ancestry, the number of alleles
carrying seven or more repeats is reported to be 49.5% [9]. The
TATA-box region is the binding site for the transcription factor
IID, thereby playing an important role in the initiation of
transcription [7]. A variation in this sequence thus reduces the
efficiency and accuracy of gene expression, subsequently
leading to higher bilirubin levels [7,9,18].
The phenotypes of Crigler–Najjar syndrome types I and II
are usually associated with homozygosity or compound
heterozygosity for nonsense and/or missense mutations. A
combination of point mutations and abnormal TA repeat
numbers in the promoter region of the UGT1A1 gene has also
been described in these forms [10,19,20].
Here, the authors describe the molecular study of the
UGT1A1 gene in Portuguese patients with the clinical
diagnosis of Gilbert syndrome and Crigler–Najjar syndrome.
Material and methods
Patients
This study included 120 Caucasian Portuguese patients (77
males and 43 females, aged 12 to 45 years) with the clinical
diagnosis of Gilbert syndrome and a further patient with the
diagnosis of Crigler–Najjar syndrome type II. Twenty-six of the
Gilbert syndrome patients were described previously [17,21].
The diagnoses of Gilbert syndrome and Crigler–Najjar syn-
drome were based on standard criteria [4,5,10]. In the Gilbert
syndrome patients, the diagnosis is based by mild hyperbilir-
ubinemia (less than 100 Amol/L) occurring in the absence of
hemolysis or liver disease. The mean total bilirubin concentra-
tion of all patients with Gilbert syndrome was 36.02, range 21 to
87 Amol/L. The patient with Crigler–Najjar syndrome type II
had a basal bilirubin level of 108 Amol/L, which decreased withthe administration of phenobarbital (70 Amol/L) and increased
with fasting (198 Amol/L).
A prenatal diagnosis was also performed for a couple that
had a son affected with Crigler–Najjar syndrome type I and
homozygosity for the c.923G>A mutation.
Mutation screening
Genomic DNA was isolated from blood samples using
standard methods and from chorionic villi using DNAzol\
reagent (Invitrogen Life Technologies, California, USA).
All patients and 75 healthy Portuguese subjects with no
known history of jaundice were screened for the TA insertion in
the promoter region of UGT1A1 gene. This TATA-box region
was analyzed by PCR amplification using the primers described
by Bancroft et al. [32] (UGT1A1-TAF and UGT1A1-TAR from
Table 1), with the introduction a fluorochrome label in the
reverse primer, for subsequent analysis by automated capillary
electrophoresis.
Direct sequencing of the five exons and promoter region
(c.–1043 to c.–1568) of the UGT1A1 gene was performed in
the Gilbert syndrome patients found to be heterozygous for the
TA insertion. Table 1 describes the primers designed for the
respective PCR amplifications. Sequencing was carried out on
the primary amplicons, using the respective forward and
reverse primers, in independent sequencing reactions, with
the Dye Terminator Cycle Sequencing Kit (Perkin Elmer,
Boston, USA) and subsequently resolved on an ABI Prism 310
GeneticAnalyser (Applied Biosystems, Foster City, USA).
Sequence analysis was carried out using the reference sequence
filed under GenBank accession number 000463.
RFLA
Restriction fragment length analysis (RFLA) was performed
for carrier detection of the c.923G>A mutation and population
Fig. 2. Partial sequence around the c.923G>A mutation site in exon 2 of the
UGT1A1 gene. (A) Normal sequence. (B) Heterozygous patient. (C)
Restriction analysis of c.923G>A, using HinfI. Lane 1—undigested fragment;
lane 2—normal individual; lanes 3 and 4—heterozygous patients.
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PCR amplicons of exon 2 and the promoter region were
directly digested with HinfI and Cac8I enzymes respectively,
and the products resolved by electrophoresis on a 4% agarose
gel.
SSCA
Single-strand conformational analysis (SSCA) was per-
formed for carrier detection of the c.674T>G mutation and for
carrier and population screening of the c.488_491dupACCTand
c.997-82T>Cvariations.Ampliconsof exon1 (c.488_491dupACCT
and c.674T>G) and exon 3 (c.997-82T>C) were electrophoresed at
room temperature on 0.5MDE gels (BMAProducts, Nottingham,
UK) and visualized by conventional silver staining methods.




Among the 120 unrelated patients with Gilbert syndrome,
110 were homozygous for the [TA]7 allele ([TA]7/[TA]7) and 9
were heterozygous ([TA]6/[TA]7). One patient was a com-
pound heterozygote for two insertions, namely [TA]7/[TA]8
(Fig. 1). Among 75 healthy subjects, 5 were homozygous for
the [TA]7 allele, 40 were homozygous for the [TA]6 allele, and
29 were heterozygous. The remaining subject was compound
heterozygote for the [TA]5 and [TA]7 alleles.
Additional studies performed on the 9 GS patients seen to be
heterozygous for the [TA]7 allele revealed compound hetero-
zygosity with the c.923G>A (Gly308Glu) mutation in four
patients (Fig. 2). In another patient, the [TA]7 allele was found
to be associated in cis with the c.674T>G (Val225Gly)
mutation (Fig. 3). A further patient revealed heterozygosityFig. 1. The amplified DNA fragment was separated by automated capillary
electrophoresis and analyzed with ABI GeneScan program (Applied Biosys-
tems). (A) Homozygosity for the normal (TA)6 allele; (B) homozygosity for a
mutant (TA)7 allele; (C) our patient with (TA)7 and (TA)8 alleles.for the c.488_491dupACCT mutation (Fig. 4). This previously
not described mutation was not detected in 100 unrelated
control individuals. In this case, the family study was not
possible, and it therefore remains unknown if the two
alterations are allelic. In the remaining three [TA]7 hetero-
zygotes patients, no mutations were detected.
The patient with Crigler–Najjar syndrome type II was also a
compound heterozygote for the (TA) insertion and the
c.923G>A mutation. Direct sequencing of the UGT1A1 gene
in this patient failed to reveal additional alterations.
Additionally, we found two polymorphisms in the UGT1A1
gene, one in the promoter region (c.-1126C>T) and the other in
intron 2 (c.997-82T>C). The first was found in 4% and the
second in 30% of the 100 control individuals.
In the prenatal diagnosis, the familial c.923G>A mutation
was not detected in the DNA sample obtained from chorionic
villi. Maternal contamination was excluded in the fetal sample
using microsatellite markers D5S640, D5S2077, D5S673, D5S410,
D13S232, D13S292, D13S1243, D13S1285, DMDSTR44,
DMDSTR45, DMDSTR49 and DMDSTR50. Heterozygosity for
c.923G>A was confirmed in both parents and for the (TA)
insertion in the fetus and in the mother.
Fig. 3. Nucleotide sequence of a part of exon 1 of the UGT1A1 gene. (A)
Family study of the patients with the c.674T>G and [TA]7 mutations. (B)
Normal sequence. (C) Patient heterozygous for the c.674T>G mutation. (D)
SSCA. Lanes 1 and 2—normal individuals; lane 3—heterozygous patient.
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In the four Gilbert syndrome patients with TA insertion and
c.923G>A mutations, the average of bilirubin was 61.3 Amol/L
(SD: 23.6 Amol/L), which was higher than that found in Gilbert
syndrome patients with other genotypes (Table 2).
The mean total bilirubin level found in male patients
homozygous for the TA insertion was compared by Mann–
Whitney test and was statistically higher (P=0.008) than that
of female patients with the same genotype (39.6 Amol/L [SD:
24.07 Amol/L] versus 26.96 Amol/L [SD: 10.98 Amol/L])
(Fig. 5).
In three of the four Gilbert syndrome cases presenting
heterozygosity for the c.923G>A mutation, the parents were
seen to have normal bilirubin levels. Molecular analysis
revealed heterozygosity for the point mutation in the mother
and heterozygosity for (TA) insertion in the father, in all three
cases. In the fourth family, the mother and a maternal uncle had
high bilirubin levels (41 and 35 Amol/L, respectively). Here, the
mother was found to be compound heterozygous for c.923G>A
and the (TA) insertion, whereas the uncle was homozygous for
[TA]7. The father, however, who was also homozygous for
[TA]7, presented normal bilirubin levels (15 Amol/L).In the Gilbert syndrome patient with the c.674T>G
mutation, both this and the (TA) insertion were found in
the mother and neither were found in the father, thereby
placing the two alterations in cis. However, bilirubin levels
were normal in the mother, who had no history of intermittent
jaundice.
Analysis of the Gilbert syndrome patient with the [TA]7/
[TA]8 genotype revealed that the father carried the [TA]8
allele, and the mother carried the [TA]7 allele. Both parents had
normal bilirubin levels.
The mother of the Crigler–Najjar syndrome patient pre-
sented slight hyperbilirubinemia (22 Amol/L) and was homo-
zygous for the [TA]7 allele. The father had normal bilirubin
levels and was heterozygous for the c.923G>A mutation.
Discussion
Traditionally, Gilbert syndrome has been a diagnosis of
exclusion. Routine biochemical measurement of enzymatic
activity has never been routinely possible, but genetic testing
for Gilbert syndrome has the potential to provide a positive
diagnosis. Genetic testing also aids in patient management,
since undiagnosed Gilbert syndrome patients are often sub-
jected to invasive investigations prompted by the finding of
jaundice [4,5,10].
The (TA) insertion in the promoter region of the UGT1A1
gene was seen to be the main cause of Gilbert syndrome in
Portuguese population. This high frequency is similar to that
found in other populations. Based on the frequency observed
in Caucasians, in several studies of smaller series, Beutler et
al. [9] calculated a homozygote frequency of 15%. This
predicted value is higher than that of patients with a clinical
diagnosis of Gilbert syndrome, reflecting the existence of
other inherited or acquired factors affecting bilirubin metab-
olism, in addition to reduced glucuronidation caused by the
(TA) insertion. The awareness that the (TA) insertion is the
most frequent cause of Gilbert syndrome prompted the study
of its association with other pathologies, namely h-thalasse-
mia [22,23], sickle cell anemia [24], ABO incompatibility
[25], glucose-6-phosphate dehydrogenase deficiency [26–28],
hereditary spherocytosis [29,30,31] and neonatal icterus
[32,33].
Our male patients who were homozygous for the longer
TATAA element had a more significant increased in serum
bilirubin than females (1.5 times). This may reflect the greater
bilirubin load per kilogram of body weight males or the
inhibition of enzymatic glucuronidation by endrogenic steroids
or both [7]. These higher levels may also explain the sample
bias of 2:1 (men:women) in our group of Gilbert syndrome
patients.
In Caucasian populations, the [TA]8 allele is extremely rare
[34,35]. However, in African populations, this allele is
somewhat more common, with a frequency of 6.9% [9]. The
presence of this rare allele in Caucasian was suggested by
Iolascon et al. [34] and Tsezou et al. [35] to be a result of a
recent genetic event and not derived from a common ancestral
mutation. In effect, repeated sequences are extremely unstable
Fig. 4. Partial nucleotide sequence around the c.488_491dupACCT mutation in exon 1 of the UGT1A1 gene. (A) Normal sequence. (B) Heterozygous patient. (C)
SSCA. Lanes 1 and 2—normal individuals; lane 3—heterozygous patient.
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mechanisms, such as unequal crossing over in meiosis. The
compound heterozygote in the present study ([TA]7/[TA]8) is
very similar, to the case described by Iolascon et al. [34], in
terms of age, gender and bilirubin levels, providing evidence
for some degree of correlation between phenotype and
genotype. The production of mRNA decreases progressively
as the number of repeats increases [9]. For this reason, our
patient could have a more severe phenotype than the patients
homozygous for the [TA]7 allele.Fig. 5. Comparison of bilirubin levels among the total of patients and in male
and female patients, homozygous for the TA insertion. The box has an upper
and lower edge at 25th and 75th percentiles. The lines inside the boxes
represent median (50th percentile). The lines that are drawn from the box
represent the upper and lower limits. The circles represent the outlier values.
Table 2
Relationship between total bilirubin levels and genotypes
Patients Phenotype Allele 1 Allele 2 Bilirubin
levels (Amol/l)
(meanTSD)
110 GS [TA]7 [TA]7 32.12T18.1
4 GS [TA]7 c.923G>A 61.3T23.6




1 GS [TA]7 [TA]8 60
1 CNS [TA]7 c.923G>A 108
3 GS [TA]7 ? 46.6T29.95
GS—Gilbert Syndrome, CNS—Crigler–Najjar Syndrome.
a Family study was not possible.
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7-year-old female with Crigler–Najjar syndrome type I. This
mutation, coincident with a highly conserved residue in the
protein sequence, results in the lack of enzyme activity. The
authors identified heterozygosity for this mutation in both
parents and in one brother but did not refer to her bilirubin
levels. Surprisingly, this was found to be the second most
frequent mutation associated with Gilbert syndrome in our
population, in each case always in compound heterozygosity
with the (TA) insertion. Screening for this mutation therefore
seems important in Portuguese patients with Gilbert syndrome.
Compound heterozygosity for c.923G>A and the (TA)
insertion was also found in our patient with Crigler–Najjar
syndrome type II. No reference was found in the literature of
this combination associated with Crigler–Najjar syndrome
type II. Usually the phenotype of Crigler–Najjar syndrome
type II is associated with homozygosity or compound
heterozygosity for missense mutations. However, more rarely,
intermediate levels of hyperbilirubinemia have been observed
in heterozygote carriers of Crigler–Najjar syndrome type I
mutations who also carry a (TA) insertion in the second
allele [38,39]. The presence of this compound heterozygosity
was found in both Gilbert syndrome and Crigler–Najjar
syndrome patients, once again pointing towards the existence
of other inherited and/or acquired factors affecting bilirubin
levels.
Iolascon et al. [37] described a case of Crigler–Najjar
syndrome type II which is result of interaction of c.674T>G
and c.239_240delAG mutations and homozygosity for the
(TA) insertion. This patient inherited the c.674T>G mutation
from his mother, which is also heterozygotic to the (TA)
insertion. Like in our patient and his mother, she has the two
mutations in the same chromosome. The bilirubin level, found
in mother of our patient and in the mother of the patient
described by Iolascon et al. [37], were normal or slightly
elevated (15 and 18.7 Amol/L respectively). We think this is a
causal mutation because the valine residue is highly con-
served, none of 100 unrelated control individuals was found to
carry the mutation, and direct sequencing of UGT1A1 gene in
our patient does not detect the presence of additional
alterations.
The c.488_491dupACCT mutation was described for the
first time in the present study. This frameshift mutation results
in a premature stop codon at nucleotide 183. The drastic
alteration at polypeptide level, as well as the fact that this
mutation was not found in the 100 unrelated control
individuals, provides strong evidence that this alteration is
responsible for the Gilbert syndrome phenotype of the patient.
In conclusion, the (TA) insertion was found to be present in
all of our cases and is thus the most frequent cause of Gilbert
syndrome in our population. Other alterations in the UGT1A1
gene were also seen to be associated with Gilbert syndrome; in
particular, the c.923G>A mutation seems to be recurrently
associated with hyperbilirubinemia. Identification of this and
other mutations in the UGT1A1 gene could therefore also
contribute significantly towards diagnosis, genetic counseling
and prenatal diagnosis.References
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